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OBJECTIVES The present study determined the incidence and time course of atrial fibrillation (AF)
recurrences in patients with a history of AF and fitted with an implantable monitoring device.
BACKGROUND The long-term risk of undetected recurrence of AF in patients receiving stable antiarrhythmic
therapy remains uncertain.
METHODS In 110 patients with a class I indication for physiologic pacing and a history of AF, a
pacemaker with dedicated functions for AF detection and electrogram storage was implanted,
and antiarrhythmic drug treatment was optimized. Patients were regularly followed up with
evaluation of AF-related symptoms, a resting electrocardiogram (ECG), and interrogation of
device memory. The incidence of AF recurrences lasting 48 h in asymptomatic patients
presenting in sinus rhythm (SR) at the respective follow-up visit constituted the primary end
point of this prospective study.
RESULTS During 19  11 months, 678 follow-up visits were performed. Atrial fibrillation was
documented in 51 patients (46%) by ECG recording and in 97 patients (88%) by a review of
stored electrograms (p  0.0001). Device interrogation revealed AF recurrences lasting 48
h in 50 patients, 19 of whom (38%) were completely asymptomatic and in SR at subsequent
follow-up. In 11 (16%) of 67 patients with device-confirmed freedom from AF for 3
months, AF lasting 48 h recurred subsequently.
CONCLUSIONS This prospective study demonstrates a high incidence of recurrent AF despite optimized
antiarrhythmic therapy. Of particular note, AF relapses48 h remained totally asymptomatic
in a significant proportion of patients. Freedom from AF for 3 months did not preclude
subsequent long-lasting AF recurrence. (J Am Coll Cardiol 2004;43:47–52) © 2004 by the
American College of Cardiology Foundation
Atrial fibrillation (AF), the most commonly encountered
clinical arrhythmia, is associated with increased mortality
and morbidity (1,2), largely due to thromboembolic com-
plications, including ischemic stroke (3–5). Atrial fibrilla-
tion is often associated with typical symptoms such as
palpitations, dyspnea, dizziness, and syncope (6–10), but a
significant proportion of patients remain asymptomatic.
See page 53
Such clinically silent AF carries important prognostic im-
plications, as recently emphasized in two large prospective
trials on rate versus rhythm control in AF (11,12). The
incidence of complications was higher in patients in whom
sinus rhythm (SR) appeared to be restored and maintained
compared with those who were subjected only to rate
control. This finding may be related to episodes of unde-
tected asymptomatic AF, which may keep patients at
continued risk for stroke. The prevalence of asymptomatic
AF found incidentally on clinical examination is 20%
(13,14). Studies using Holter monitoring (15), transtele-
phonic monitoring (16,17), or event recorders (18) have
reported an even higher prevalence. One study using im-
plantable pacemakers for AF detection has reported an
incidence of 50% of asymptomatic AF (19). However, this
study was restricted to a one-month follow-up period, and
the pacemakers did not have intracardiac electrogram stor-
age capabilities for verification of atrial arrhythmias. Thus,
the present prospective study aimed at the evaluation of AF
recurrences, particularly asymptomatic ones, over a long
observation period in patients fitted with a new implantable
pacemaker with sophisticated arrhythmia documentation
capabilities.
METHODS
Patient population. Patients were eligible for the study if
they had a documented history of paroxysmal or persistent
AF (at least 2 episodes in the previous 3 months), were
available for long-term follow-up, and had a class I indica-
tion for physiologic pacing (sick sinus syndrome or atrio-
ventricular [AV] block). Patients with permanent AF were
excluded from the study. All patients gave written, informed
consent. The study was approved by the institutional review
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committee, and all procedures were in accordance with
institutional guidelines.
Implantable monitoring device. All patients were im-
planted with an AT500 pacemaker capable of monitoring
and treating AF (Medtronic, Inc., Minneapolis, Minne-
sota). This device offers a special algorithm for detection of
atrial tachyarrhythmias, as described in detail elsewhere
(20); the algorithm has been shown to have a sensitivity of
100% and a specificity of 98% for AF detection (21).
Dedicated memory functions provide quantitative data, such
as the number of detected AF episodes, the total time spent
in AF since the previous follow-up visit, and the duration of
each AF episode. Up to 35 stored individual AF episodes
with atrial electrograms and marker/cycle length annota-
tions allow verification of correct detection of the onset and
end of each AF episode.
Study design. All patients were in SR at the time of
pacemaker implantation. After implantation, device pro-
gramming was performed, including activation of all AF-
related memory functions. Devices were programmed to the
DDD mode (lower rate limit 60 beats/min, upper rate limit
120 beats/min), with the rate response activated if chrono-
tropic sinus node incompetence was present and with the
AV delay programmed as long as necessary to allow spon-
taneous AV conduction in patients without AV block. For
the purpose of this study, the dedicated algorithms of the
device for prevention and termination of atrial tachyarrhyth-
mias were not activated. The first device interrogation was
performed one month after implantation with interrogation
of all memory data; further device interrogations were
scheduled at three and six months after implantation and at
six-month intervals thereafter. Additionally, interim visits
were performed as clinically indicated—for example, in the
presence of symptoms. At each follow-up visit, a 12-lead
resting electrocardiogram (ECG) and a telemetric ECG
with simultaneous intracardiac recordings were obtained.
Patients were also subjected to standardized interviews to
verify the presence or absence of the most important
AF-related symptoms (rapid and/or irregular heart beat,
palpitations, dyspnea, syncope, or presyncope) (6–9) since
the previous follow-up visit. Device-stored data were down-
loaded to diskette and subsequently analyzed by an investi-
gator who was unaware of the patients’ symptomatic status
and findings on the follow-up ECG. Episodes of AF were
printed out, and correct classification was verified by analysis
of stored electrograms. Antiarrhythmic drug therapy was
optimized if necessary over the first month after pacemaker
implantation and maintained constant for the remainder of
the study period. All patients were receiving oral anticoag-
ulation therapy (target International Normalized Ratio 2.0
to 3.0), except for those with contraindications and those in
whom only short (1 h) paroxysms of AF had been
previously detected.
Study end points and statistics. The primary study end
point was defined as the incidence of AF lasting 48 h, as
documented by the implanted device in asymptomatic
patients presenting in SR at the time of the follow-up visit.
This duration was selected based on current guidelines (22),
which recommend anticoagulation therapy to prevent
thromboembolic complications in AF lasting 48 h. In
patients whose stored electrograms documented that the
true AF onset was not detected by the device but in whom
intermittent atrial undersensing of small AF potentials was
present, the daily cumulative time in AF during consecutive
days was considered. If the patient experienced three con-
secutive days of AF for20 h/day each, the AF episode was
considered as one single, ongoing episode lasting 48 h
with intermittent atrial undersensing. Secondary end points
were the incidence of ECG- versus device-based documen-
tation of AF and the incidence of AF lasting 48 h after
freedom from AF for 3 months. Electrocardiogram-
versus device-based documentation of AF was compared
over time using Kaplan-Meier analysis, along with the
Wilcoxon rank-sum test. The cumulative incidence of AF
detection by devices versus ECG was compared using the
Table 1. Patient Characteristics
Gender
Female 47 (43%)
Male 63 (57%)
Type of AF (mutually exclusive)
Paroxysmal 54 (49%)
Persistent 56 (51%)
Bradycardia
Sick sinus syndrome 70 (64%)
AV block 40 (36%)
Cardiovascular disease
Hypertension 70 (64%)
Coronary artery disease 51 (46%)
Valvular disease 36 (33%)
Cardiomyopathy 9 (8%)
None 18 (16%)
Echocardiographic parameters
Left atrial diameter (mm) 47  9
Left ventricular ejection fraction (%) 0.53  0.14
Antiarrhythmic drug treatment
Class I 4 (4%)
Beta-blockers 45 (41%)
Amiodarone 24 (22%)
Sotalol 20 (18%)
Calcium antagonists* 12 (11%)
Digitalis 18 (16%)
None 20 (18%)
Anticoagulation
Coumadin (INR 2.0–3.0) 78 (71%)
*Only diltiazem and verapamil. Data are presented as the number (%) of patients or
mean value  SD.
AF  atrial fibrillation; AV  atrioventricular; INR  international normalized
ratio.
Abbreviations and Acronyms
AF  atrial fibrillation
AV  atrioventricular
ECG  electrocardiogram/electrocardiographic
SR  sinus rhythm
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Fisher exact test. Statistical significance was assumed at p 
0.05.
RESULTS
Patient characteristics. A total of 110 patients were en-
rolled in the study: 63 men and 47 women (mean age 68 
9 years) (Table 1). Fifty-six patients (51%) had a history of
persistent AF with at least one cardioversion attempt (range
1 to 6); the remainder had a history of paroxysmal AF.
Seventy patients (64 %) had AF associated with sick sinus
syndrome. Bradycardia was drug-associated in 28 patients
(25%). The most frequent underlying cardiovascular disease
was hypertension. Coronary artery disease confirmed by
angiography was present in 51 patients (46%) and lone AF
in 16% of patients. A left atrial diameter 40 mm was
documented in 79% of patients (50 mm in 38%); left
ventricular function was severely depressed (ejection fraction
0.35) in 24% of patients. All patients had clinical (age
65 years, hypertension, history of transient ischemic
attack or stroke, diabetes, congestive heart failure, mitral
stenosis) and/or echocardiographic (left atrial dilation, re-
duced left ventricular function) risk factors for stroke.
Twelve patients had a history of stroke, transient ischemic
attack, or peripheral embolism. Ninety patients (82%)
received negative dromotropic drugs, mostly beta-blockers.
Class I or III antiarrhythmic drugs were prescribed in 44%
of patients. Seventy-eight patients (71%) were on oral
anticoagulation, and 32 patients either had contraindica-
tions (n  10), declined anticoagulation (n  12), or had
previously exhibited only short paroxysms of AF (n  10).
During the study period, 25 external cardioversions were
performed in 18 patients.
Recurrence of AF during follow-up. Patients were fol-
lowed for a mean of 19 11 months (range 6 to 42), during
which time a total of 678 follow-up visits took place
(median 7 per patient [range 3 to 14]). With respect to
thromboembolic complications, there was one peripheral
embolism in a patient not on anticoagulation. Bleeding
complications were not observed.
Fifty patients had device-documented AF episodes last-
ing 48 h. Of these, 19 (38%) were asymptomatic and
presented in SR at the respective follow-up visit (Fig. 1).
Among patients with AF 48 h, no clinical or echocardio-
graphic variables were predictive of the lack of symptoms; in
particular, the percentage of patients with asymptomatic AF
48 h with a history of paroxysmal or persistent AF was
identical (17% vs. 18%). In 51 (46%) of 110 patients, AF
was documented by the resting ECG during follow-up,
whereas device interrogation revealed episodes of AF in 97
patients (88%; p  0.0001) (Fig. 2). In 57 patients (59% of
patients with device-detected AF episodes and 52% of the
total patient group), asymptomatic AF recurrence was
detected in at least one follow-up period solely by the
implanted monitoring device. Device-documented AF re-
currence lasted 72 h in 42 patients (38%), 48 h in 50
patients (45%), 24 h in 58 patients (53%), and 12 h in
70 patients (64%). In 24 patients (22%), all recorded AF
episodes were 12 h in duration (Fig. 3). In 44 patients
(40%), AF-related symptoms were reported while the ECG
and device memory showed absence of AF. Symptoms
related to AF combined with ECG recordings at follow-up
had a sensitivity of 68% and a specificity of 57% for AF
detection.
Recurrence of AF after freedom from AF for>3 months.
Sixty patients (55%) were free of AF for 3 months,
according to a lack of AF-related symptoms and documen-
tation of SR at follow-up. Of these, 14 (23%) developed
device-documented asymptomatic AF recurrence lasting
48 h during subsequent follow-up. In 67 (61%) of the 110
patients, device memory confirmed freedom from AF for
3 months. In 11 of these (16%), symptomatic or asymp-
tomatic AF recurrences lasting 48 h were observed during
Figure 1. Cumulative incidence of asymptomatic atrial fibrillation recurrence48 h not detected by serial electrocardiographic recordings during follow-up
(FU) visits.
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further follow-up by continuous device monitoring. The
longest period of freedom from AF before a device-
documented AF recurrence 72 h was 20 months. There
was no statistical relationship between any specific antiar-
rhythmic treatment regimen (beta-blockers, class III anti-
arrhythmic drugs, calcium antagonists, and digitalis) and
the occurrence of asymptomatic AF episodes 48 h.
DISCUSSION
Main study findings. This prospective long-term
follow-up study is the first to use continuous ECG moni-
toring by an implantable device for up to 42 months to
document recurrences of AF and the exact duration of
arrhythmia-free intervals and AF episode duration. It dem-
onstrates that AF recurrences of48-h duration are asymp-
tomatic in more than one-third of patients with a history of
paroxysmal or persistent AF. Moreover, in 16% of patients
with a history of AF, recurrences of48-h duration develop
even after documentation of freedom from AF for three
months or longer. These observations demonstrate that the
success rates of maintaining continuous SR in patients with
a history of AF are often grossly overestimated. Our
findings have important clinical implications for the treat-
ment of patients with AF.
Prevalence of symptomatic AF. The majority of patients
with AF documented by the implanted monitoring devices
reported symptoms during the respective follow-up period.
This is in agreement with previous studies correlating
standard ECG recordings with symptoms suggestive of the
presence of AF (7,13,14). However, the association between
symptoms and AF is weak. Forty percent of patients in the
present study reported symptoms suggestive of AF, but
device interrogation proved the absence of AF during the
respective follow-up period. Palpitations and perception of
an irregular heart beat may also be caused by single or short
runs of atrial premature beats, limiting the specificity and
diagnostic reliability of symptoms potentially associated
with AF. The wide variability in AF perception may also
have constituted one reason for the lack of any difference in
quality of life between patients assigned to rhythm versus
rate control in prospective trials (11,23).
Prevalence of asymptomatic AF. Data on the prevalence
of asymptomatic AF primarily depend on the method used
for documentation. Studies using single or repeated surface
ECG recordings obtained during a clinical visit found a
prevalence of asymptomatic AF of 5% to 20% in unselected
patient groups (7,13,14,24,25). Holter monitoring only
slightly increases the diagnostic yield to detect asymptom-
atic AF (15,26). Event recorders can extend the monitoring
duration up to one month but are unable to detect patients
with silent AF if ECG storage is only triggered by patients’
symptoms. Based on these diagnostic tools, the true recur-
rence rate of AF, particularly asymptomatic forms, remains
Figure 2. Cumulative incidence of detection of any atrial fibrillation recurrence by electrocardiographic recording during follow-up (FU) (solid line) versus
information from the implanted device (dashed line). n  number of patients at risk.
Figure 3. Prevalence of atrial fibrillation (AF) recurrences of various
durations detected during follow-up.
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uncertain. To reduce this diagnostic gap, event recorders
that can automatically detect and store arrhythmias during a
continuous monitoring period of seven days have been
developed (18). Using this automatic storage mode, parox-
ysmal AF was diagnosed in 20 of 65 patients with recurrent
palpitations and a negative 24-h Holter recording. Tran-
stelephonic ECG transmission has been used to provide a
“daily snapshot” of the atrial rhythm. In the Prevention of
Atrial Fibrillation After Cardioversion (PAFAC) trial,
2,100 ECG recordings transmitted transtelephonically on a
daily basis showed AF (17). Of these recordings, 75% were
asymptomatic.
Implanted devices such as pacemakers or implantable
cardioverter-defibrillators with atrial electrograms provide
continuous rhythm monitoring and may thus enhance the
diagnostic accuracy of detection of asymptomatic AF (27).
This has been suggested in the Automatic Interpretation for
Diagnostic Assistance (AIDA) trial, in which paroxysms of
AF 1 min were recorded by the devices in half of the
patients; 58% of these patients were completely asymptom-
atic (19). However, this study was limited by a short
observation period of only 28 days and particularly by the
lack of device-stored electrograms to prove the presence of
AF. The present study is unique because it provides con-
tinuous atrial rhythm monitoring over a mean period of
18 months, using a highly sensitive and specific algorithm
for AF detection. These data therefore provide fundamen-
tally more accurate information on the occurrence of sus-
tained asymptomatic AF than data derived from daily
transtelephonic ECG transmissions of a few seconds only or
event recording for one to two weeks. The present study
demonstrates that asymptomatic AF escaped documenta-
tion by ECG recording during follow-up in 59% of patients.
This emphasizes the underestimation of AF recurrences
based solely on the evaluation of symptoms and repeated
ECG recordings, which was demonstrated also in the subset
of patients with AF recurrences lasting 48 h.
Clinical implications of asymptomatic AF. The underes-
timated prevalence of recurrent AF, particularly asymptom-
atic AF, in patients deemed to be successfully maintained in
SR has obvious clinical implications. For instance, the
efficacy of pharmacologic and nonpharmacologic treatment
modalities (i.e., catheter ablation of AF) may be signifi-
cantly overestimated in clinical studies, as well as in everyday
clinical practice. The most apparent clinical implications of
our findings relate to the need for anticoagulation in
patients with AF. In the recently published Atrial Fibrilla-
tion Follow-up Investigation of Rhythm Management (AF-
FIRM) study, the lack of clinical benefit of the strategy of
maintaining SR was partly due to the high incidence of
stroke in patients believed to be in SR and in whom
anticoagulation was subsequently withdrawn (11). The
present study strongly supports the notion that according to
current clinical guidelines (22) a significant proportion of
patients with asymptomatic, undetected AF continue to be
at increased risk for ischemic stroke after withdrawal of
anticoagulation. Even if “full disclosure” of the atrial rhythm
is available (as realized by the implanted device in our
study), 16% of patients free from any AF episode for 3
months developed persistent AF during further follow-up.
Therefore, our findings reemphasize the conclusion drawn
by the AFFIRM investigators (11) in that patients at
increased risk for stroke should continue on anticoagulation
even in the presence of seemingly stable SR.
Study limitations. All patients who received the implant-
able device with dedicated monitoring features for AF also
had a class I indication for physiologic pacing. Therefore,
the findings in our study apply to patients with bradycardia
requiring pacing. However, it is likely that most of our
observations can also be applied to patients with AF and
antiarrhythmic drug treatment in the absence of bradycar-
dia. Patients did not record their symptoms in a diary or use
a manual activator that triggers device storage of symptoms.
Therefore, some patients may not have been able to recall
their symptoms during the follow-up visit. However, this
corresponds to clinical routine follow-up care of patients
with AF. The device used in the present study offers no
information on the number of detected atrial or ventricular
premature beats or short atrial runs which may have
occurred and may explain symptoms in patients without
detected AF episodes.
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